BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26729196)

  • 1. Immunotherapy of biliary tract cancer.
    Chai Y
    Tumour Biol; 2016 Mar; 37(3):2817-21. PubMed ID: 26729196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic Approaches to Biliary Cancer.
    Shah UA; Nandikolla AG; Rajdev L
    Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of novel biologics in biliary cancers.
    Jordan E; Braghiroli MF; Lowery MA
    Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for immune-based approaches in biliary tract carcinoma.
    Duffy AG; Makarova-Rusher OV; Greten TF
    Hepatology; 2016 Nov; 64(5):1785-1791. PubMed ID: 27177447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers].
    Goeppert B
    Pathologe; 2017 Nov; 38(Suppl 2):192-197. PubMed ID: 29063951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advance in immunotherapy on biliary tract cancers].
    Liu LG; Zhang YJ; Wang XA; Liu YB
    Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):156-160. PubMed ID: 33378809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.
    Palmieri LJ; Lavolé J; Dermine S; Brezault C; Dhooge M; Barré A; Chaussade S; Coriat R
    Pharmacol Ther; 2020 Jun; 210():107517. PubMed ID: 32109491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Progress in Immunotherapy for the Treatment of Biliary Cancers.
    Pauff JM; Goff LW
    J Gastrointest Cancer; 2016 Dec; 47(4):351-357. PubMed ID: 27538880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets.
    Tariq NU; Vogel A; McNamara MG; Valle JW
    Oncol Res Treat; 2018; 41(5):298-304. PubMed ID: 29705791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 17. Current progress in systemic therapy for biliary tract cancers.
    Sutherland M; Ahmed O; Zaidi A; Ahmed S
    J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1094-1107. PubMed ID: 33735541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
    Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
    Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
    Hack SP; Zhu AX
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.